NovoCure (NVCR) Cost of Revenue (2014 - 2026)

NovoCure (NVCR) has reported Cost of Revenue for 13 consecutive years, with $41.1 million the latest figure, recorded in Q2 2026.

• Quarterly Cost of Revenue fell 0.88% year-over-year to $41.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $166.9 million (up 12.15% YoY) and the FY2025 annual result came in at $166.9 million, up 21.65% from the prior year.
• Cost of Revenue grew to $41.1 million in Q2 2026 per NVCR's latest filing, from $38.9 million in the prior quarter.
• Over the last five years, Cost of Revenue for NVCR reached as high as $44.7 million in Q3 2025 and fell as low as $27.7 million in Q1 2022.
• A 5-year average of $34.8 million and a median of $33.9 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue decreased 2.69% — and 2025, when it gained 26.45%.
• Year by year, Cost of Revenue stood at $28.9 million in 2022, then advanced by 12.7% to $32.6 million in 2023, then gained by 2.8% to $33.5 million in 2024, then gained by 25.97% to $42.2 million in 2025, then slipped by 2.49% to $41.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $41.1 million, $38.9 million, and $42.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.